Supplementary material to article by J. M. Sobell et al. "Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis"




Fig. S1. Design of the ESTEEM 1 and 2 studies. *Doses of apremilast were titrated during the first week of administration and at Week 16 when placebo patients were switched to apremilast. *PASI-75 (ESTEEM 1) or PASI-50 (ESTEEM 2). 'In ESTEEM 1, patients were switched to apremilast at the time of loss of PASI-75, but no later than Week 52. In ESTEEM 2, patients were switched to apremilast at time of loss of effect, defined as time of loss of 50% of the PASI improvement obtained at Week 32 compared to baseline, but no later than Week 52.'Patients initially on placebo or randomized to apremilast 30 mg BID who did not attain a PASI-75 (ESTEEM 1) or PASI-50 (ESTEEM 2) were able to add topicals and/or UVB at Week 32 at the discretion of the investigator.